[go: up one dir, main page]

DE60318177D1 - Rho-kinase inhibitoren - Google Patents

Rho-kinase inhibitoren

Info

Publication number
DE60318177D1
DE60318177D1 DE60318177T DE60318177T DE60318177D1 DE 60318177 D1 DE60318177 D1 DE 60318177D1 DE 60318177 T DE60318177 T DE 60318177T DE 60318177 T DE60318177 T DE 60318177T DE 60318177 D1 DE60318177 D1 DE 60318177D1
Authority
DE
Germany
Prior art keywords
rho
kinase inhibitors
compounds
treating
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318177T
Other languages
English (en)
Other versions
DE60318177T2 (de
Inventor
Dhanapalan Nagarathnam
Jacques Dumas
Holia Hatoum-Mokdad
Stephen Boyer
Hans Pluempe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of DE60318177D1 publication Critical patent/DE60318177D1/de
Application granted granted Critical
Publication of DE60318177T2 publication Critical patent/DE60318177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60318177T 2002-01-23 2003-01-23 Rho-kinase inhibitoren Expired - Lifetime DE60318177T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34998602P 2002-01-23 2002-01-23
US349986P 2002-01-23
PCT/US2003/001840 WO2003062227A1 (en) 2002-01-23 2003-01-23 Rho-kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60318177D1 true DE60318177D1 (de) 2008-01-31
DE60318177T2 DE60318177T2 (de) 2008-10-09

Family

ID=27613348

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318177T Expired - Lifetime DE60318177T2 (de) 2002-01-23 2003-01-23 Rho-kinase inhibitoren

Country Status (9)

Country Link
US (3) US6943172B2 (de)
EP (1) EP1470122B1 (de)
JP (1) JP4423043B2 (de)
AT (1) ATE381557T1 (de)
CA (1) CA2473910C (de)
DE (1) DE60318177T2 (de)
ES (1) ES2298497T3 (de)
MX (1) MXPA04007196A (de)
WO (1) WO2003062227A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1370553T3 (da) * 2001-03-23 2006-09-11 Bayer Corp Rho-kinase-inhibitorer
AR035792A1 (es) * 2001-03-23 2004-07-14 Bayer Corp Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
AU2003202263A1 (en) * 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
WO2003062225A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
ES2298497T3 (es) * 2002-01-23 2008-05-16 Bayer Pharmaceuticals Corporation Inhibidores de quinasa rho.
DE10226943A1 (de) * 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
EP1644365A2 (de) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazin- und pyridinderivative als rho-kinase-inhibitoren
PT1663978E (pt) 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
EP1689722A2 (de) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation Pyrimidinderivate zur behandlung von hyperproliferativen erkrankungen
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
DE102004020570A1 (de) 2004-04-27 2005-11-24 Bayer Healthcare Ag Substituierte Phenylaminopyrimidine
US20060142193A1 (en) * 2004-11-09 2006-06-29 Baylor College Of Medicine Selective inhibition of rock1 in cardiac therapy
GB0500226D0 (en) * 2005-01-07 2005-02-16 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
CN101151258A (zh) * 2005-03-10 2008-03-26 拜尔药品公司 用于治疗过度增生病症的嘧啶衍生物
CN101198354B (zh) 2005-06-21 2012-01-11 兴和株式会社 青光眼的预防或治疗剂
CN101198355B (zh) 2005-07-12 2010-11-10 兴和株式会社 预防或治疗青光眼的药剂
JP2007161608A (ja) * 2005-12-09 2007-06-28 Fujifilm Finechemicals Co Ltd Ｎ−（ヘテロ）アリール置換含窒素ヘテロアリール化合物の製造方法
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
RU2008130111A (ru) 2005-12-22 2010-01-27 Алькон Рисерч, Лтд. (Us) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
WO2007146981A2 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
JP2008063278A (ja) * 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
JP5657252B2 (ja) 2007-08-29 2015-01-21 千寿製薬株式会社 角膜内皮細胞接着促進剤
WO2009047255A1 (en) * 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
AU2009215430B2 (en) * 2008-02-22 2015-02-12 Rigel Pharmaceuticals, Inc. Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
US8557580B2 (en) 2009-02-20 2013-10-15 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
US8372642B2 (en) * 2009-02-27 2013-02-12 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
EP3904505A1 (de) 2009-04-22 2021-11-03 Viacyte, Inc. Zellzusammensetzungen aus entdifferenzierten neuprogrammierten zellen
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9005968B2 (en) 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
AU2010315712B2 (en) 2009-10-19 2014-04-17 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte production
RU2528386C2 (ru) 2010-05-21 2014-09-20 Кемилиа Аб Новые производные пиримидина
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
EP3553168B1 (de) 2010-11-12 2025-12-31 Georgetown University Immortalisierung von epithelzellen und verfahren zur verwendung
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
EP2694644B1 (de) 2011-03-30 2018-01-24 Cellular Dynamics International, Inc. Priming pluripotenter stammzellen für neurale differenzierung
EP2732029B1 (de) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Verfahren zur zellprogrammierung und genommanipulation
PT2788472T (pt) 2011-12-06 2019-04-01 Astellas Inst For Regenerative Medicine Método de diferenciação dirigida para a produção de células endoteliais corneanas
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
EP2826855B1 (de) 2012-03-15 2018-08-29 iHeart Japan Corporation Myocardiale zellschicht
JP6112733B2 (ja) 2012-04-06 2017-04-12 国立大学法人京都大学 エリスロポエチン産生細胞の誘導方法
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
AU2013325615A1 (en) 2012-10-02 2015-04-09 Sumitomo Dainippon Pharma Co., Ltd. Imidazole derivative
CA2899507A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
CN105358680B (zh) 2013-04-03 2019-06-25 富士费勒姆细胞动力学有限公司 用于悬浮培养内胚层祖细胞的方法和组合物
WO2014168264A1 (ja) 2013-04-12 2014-10-16 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
EP3020803B1 (de) 2013-06-11 2020-03-11 Kyoto University Verfahren zur herstellung von nierenvorläuferzellen
WO2015016371A1 (ja) 2013-07-30 2015-02-05 京都府公立大学法人 角膜内皮細胞マーカー
US9796962B2 (en) 2013-08-07 2017-10-24 Kyoto University Method for generating pancreatic hormone-producing cells
CA2923592A1 (en) 2013-09-05 2015-03-12 Kyoto University Method for inducing dopamine-producing neural precursor cells from pluripotent stem cells
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
RU2712967C2 (ru) 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
JP6470286B2 (ja) 2013-11-27 2019-02-13 京都府公立大学法人 ラミニンの角膜内皮細胞培養への応用
WO2015134652A1 (en) 2014-03-04 2015-09-11 Bahram Valamehr Improved reprogramming methods and cell culture platforms
EP3119881B1 (de) 2014-03-21 2023-03-01 FUJIFILM Cellular Dynamics, Inc. Herstellung von von dopaminergischen neuronen aus dem mittelhirn
WO2015178431A1 (ja) 2014-05-21 2015-11-26 国立大学法人京都大学 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤
WO2015200920A1 (en) 2014-06-27 2015-12-30 The Regents Of The University Of California Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
AU2015353853B2 (en) 2014-11-25 2020-10-15 President And Fellows Of Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CA2981708C (en) 2015-04-03 2024-09-10 Propagenix Inc. EX VIVO PROLIFERATION OF EPITHELIAL CELLS
DK3347450T3 (da) 2015-09-11 2021-05-31 Propagenix Inc Ex vivo-proliferation af epithelceller
JP7263005B2 (ja) 2015-10-16 2023-04-24 フェイト セラピューティクス，インコーポレイテッド 基底状態の多能性の誘導及び維持に関するプラットフォーム
AU2016343682A1 (en) 2015-10-30 2018-06-14 The Regents Of The University Of California Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
PL3416658T3 (pl) 2016-02-15 2023-09-04 Kyoto Prefectural Public University Corporation Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
JP7120993B2 (ja) 2016-08-16 2022-08-17 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性細胞を分化させるための方法
JP7161775B2 (ja) 2017-05-25 2022-10-27 国立大学法人京都大学 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法
WO2019092939A1 (ja) 2017-11-10 2019-05-16 株式会社リジェネシスサイエンス 培養細胞の製造方法，脊髄損傷疾患の治療剤の製造方法
EP3733837A4 (de) 2017-12-28 2021-10-06 Kaneka Corporation Mittel zur förderung der zellaggregation
CN111542598B (zh) 2017-12-28 2024-07-30 株式会社钟化 多能干细胞聚集抑制剂
WO2019131941A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 細胞凝集抑制剤
US20200405768A1 (en) 2018-02-19 2020-12-31 Sumitomo Dainippon Pharma Co., Ltd. Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same
US20210332329A1 (en) 2018-07-23 2021-10-28 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
US20210189351A1 (en) 2018-08-20 2021-06-24 Propagenix Inc. Epithelial cell spheroids
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CN113056556A (zh) 2018-08-31 2021-06-29 学校法人同志社 用于对眼细胞进行保存或培养的组合物以及方法
CA3109705A1 (en) 2018-10-02 2020-04-09 The Doshisha Method and vessel for preserving corneal endothelial cells
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
US20220169977A1 (en) 2019-03-29 2022-06-02 Kaneka Corporation Cell population including pluripotent stem cells and production method thereof
WO2020230832A1 (ja) 2019-05-15 2020-11-19 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
BR112022017180A2 (pt) 2020-02-27 2022-10-18 Kyoto Prefectural Public Univ Corp Células endoteliais da córnea humanas funcionais e aplicação das mesmas
WO2021220132A1 (en) 2020-04-27 2021-11-04 Novartis Ag Methods and compositions for ocular cell therapy
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids
AU2022256048A1 (en) 2021-04-07 2023-10-05 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
BR112023021993A2 (pt) 2021-05-03 2024-02-20 Astellas Inst For Regenerative Medicine Métodos de geração de células endoteliais da córnea madura
EP4353243A4 (de) 2021-06-10 2025-06-25 Ajinomoto Co., Inc. Verfahren zur herstellung mesenchymaler stammzellen
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
US20230078230A1 (en) 2021-09-13 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
EP4419649A1 (de) 2021-10-18 2024-08-28 Evia Life Sciences Inc. Zusammensetzungen und verfahren zur verwendung davon zur behandlung von leberfibrose
JP2024539220A (ja) 2021-10-22 2024-10-28 エヴィア ライフ サイエンシズ インコーポレイテッド 細胞外小胞を作製するための方法、組成物、およびその使用方法
JPWO2023085369A1 (de) 2021-11-11 2023-05-19
WO2023090427A1 (ja) 2021-11-19 2023-05-25 国立研究開発法人理化学研究所 シート状網膜組織の製造方法
US20250145948A1 (en) 2022-02-09 2025-05-08 Sumitomo Pharma Co., Ltd. Method for assessing differentiation potential of cells in culture broth in differentiation of pluripotent stem cells into neural cells of midbrain floor plate region
CN119790139A (zh) 2022-08-31 2025-04-08 国立大学法人京都大学 原始态多能干细胞的制造方法
CN119948151A (zh) 2022-09-26 2025-05-06 国立大学法人京都大学 胰腺内胚层细胞的制造方法
JP2025532957A (ja) 2022-09-30 2025-10-03 フジフィルム セルラー ダイナミクス，インコーポレイテッド 心臓線維芽細胞の作製方法
EP4678737A1 (de) 2023-03-03 2026-01-14 Kyoto University Verfahren zur herstellung von vorbehandelten pluripotenten stammzellen
TW202444894A (zh) 2023-03-29 2024-11-16 日商住友製藥股份有限公司 視網膜組織之製造方法
WO2024242069A1 (ja) 2023-05-19 2024-11-28 国立大学法人京都大学 神経堤細胞の製造方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642347A (en) 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
ATE156120T1 (de) 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5245036A (en) 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
EP1195372A1 (de) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
US5840695A (en) 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0912559B1 (de) 1996-07-13 2002-11-06 Glaxo Group Limited Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
CZ301044B6 (cs) 1996-08-12 2009-10-21 Mitsubishi Tanabe Pharma Léciva obsahující amidové deriváty inhibující Rho kinázu
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5885803A (en) 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
HRP20000885B1 (hr) 1998-06-19 2007-03-31 Pfizer Products Inc. PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI
US6673812B1 (en) 1998-08-17 2004-01-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
SE515247C2 (sv) 1998-09-04 2001-07-02 Alfa Laval Agri Ab Djurbås med fösningsorgan
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911510A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU3328600A (en) 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
HK1042656A1 (en) 1999-03-25 2002-08-23 三菱制药株式会社 Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
EP1174150A4 (de) 1999-04-22 2004-06-16 Mitsubishi Pharma Corp Präventiv-/heilmittel für angiostenose
DE60045890D1 (de) 1999-04-27 2011-06-09 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU1212501A (en) * 1999-10-21 2001-04-30 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
HUP0302221A3 (en) 2000-09-20 2004-01-28 Merck Patent Gmbh 4-amino-quinazolines
AU2001296846B2 (en) 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
AU2002246924A1 (en) 2001-01-05 2002-07-16 The Medical College Of Georgia Research Institute, Inc. Treatment of erectile dysfunction with rho-kinase inhibitors
ES2298497T3 (es) * 2002-01-23 2008-05-16 Bayer Pharmaceuticals Corporation Inhibidores de quinasa rho.

Also Published As

Publication number Publication date
JP4423043B2 (ja) 2010-03-03
ATE381557T1 (de) 2008-01-15
EP1470122A1 (de) 2004-10-27
WO2003062227A1 (en) 2003-07-31
US20120302587A1 (en) 2012-11-29
JP2005523894A (ja) 2005-08-11
US20050209261A1 (en) 2005-09-22
US20040002507A1 (en) 2004-01-01
MXPA04007196A (es) 2005-06-08
CA2473910C (en) 2011-03-15
US6943172B2 (en) 2005-09-13
EP1470122B1 (de) 2007-12-19
ES2298497T3 (es) 2008-05-16
DE60318177T2 (de) 2008-10-09
CA2473910A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DE60318177D1 (de) Rho-kinase inhibitoren
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
MXPA05003273A (es) Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos.
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
ATE240328T1 (de) Substituierte azaoxindolederivate
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
ATE343575T1 (de) Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
NO20044526L (no) Hemisterlinderivater og anvendelser derav
NO20054494L (no) Peptidvektorer
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
SE0203747D0 (sv) New use
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf
SG145571A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
ATE293107T1 (de) Luminacine analoge und deren verwendung
CY1114194T1 (el) Αναστολεις δραστικοτητας ακτ
SV2004000934A (es) Inhibidores de la rho-quinasa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER HEALTHCARE, LLC, TARRYTOWN, N.Y., US